CD3-directed Antibody Interactions

Name

CD3-directed Antibody Interactions

Accession Number

DBCAT004330

Description

Not Available

Drugs

Drug	Drug Description
Muromonab	A monoclonal anti-CD3 antibody used as immunosuppressive therapy in kidney, heart, and liver transplant patients.
Blinatumomab	An antineoplastic antibody used to treat CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients, as well as those in first or second complete remission with minimal residual disease (MRD).
Mosunetuzumab	A humanized anti-CD20/CD3 bispecific antibody used to treat relapsed or refractory follicular lymphoma.
Teplizumab	A CD3-directed monoclonal antibody indicated to delay the onset of Stage 3 type 1 diabetes in patients with Stage 2 type 1 diabetes.
Epcoritamab	A bispecific CD20-directed CD3 T-cell engager used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults.

Drugs & Drug Targets

Drug	Target	Type
Muromonab	T-cell surface glycoprotein CD3 epsilon chain	target
Muromonab	Low affinity immunoglobulin gamma Fc region receptor III-B	target
Muromonab	T-cell surface glycoprotein CD3 delta chain	target
Muromonab	T-cell surface glycoprotein CD3 gamma chain	target
Muromonab	T-cell surface glycoprotein CD3 zeta chain	target
Blinatumomab	B-lymphocyte antigen CD19	target
Blinatumomab	T-cell surface glycoprotein CD3 delta chain	target
Mosunetuzumab	B-lymphocyte antigen CD20	target
Mosunetuzumab	T-cell surface glycoprotein CD3 epsilon chain	target
Teplizumab	T-cell surface glycoprotein CD3 epsilon chain	target
Epcoritamab	B-lymphocyte antigen CD20	target
Epcoritamab	T-cell surface glycoprotein CD3 epsilon chain	target